Bacillus spore probiotics promote respiratory and digestive health for a future without antibiotics

LiveSpo’s mission is “A Future Without Antibiotics”. In the hospital, 72% of antibiotics are prescribed for respiratory and 20% for gastrointestinal infections. They are thrilled to introduce their liquid-form Bacillus spore probiotics, including LiveSpoNAVAX for respiratory, and LiveSpoCLAUSY and LiveSpoDIA30 for digestive health enhancement. Clinical studies have shown promising results, with LiveSpo’s probiotics reducing antibiotic use by about 20% and improving symptomatic treatment of respiratory infections due to RSV and influenza virus (LiveSpoNavax) as well as persistent diarrhea (LiveSpoCLAUSY and LiveSpoDIA30) by 50-60%. With their distinctive probiotics, their goal is to substantially decrease antibiotic dependence among millions of children worldwide.